The first fully synthetic glycopeptide vaccines against a fungal disease have been used to combat disseminated candidiasis in mice. Six T cell peptides found in Candida albicans cell wall proteins were selected by algorithm peptide epitope searches; each was synthesized and conjugated to the fungal cell wall ␤-mannan trisaccharide [␤-(Man) 3] by novel saccharide-peptide linker chemistry to create glycopeptide conjugates. The six proteins were selected because of expression during human candidiasis and cell wall association and included: fructose-bisphosphate aldolase (Fba); methyltetrahydropteroyltriglutamate (Met6); hyphal wall protein-1 (Hwp1); enolase (Enol); glyceraldehyde-3-phosphate dehydrogenase (Gap1); and phosphoglycerate kinase (Pgk1). By immunization protocols favoring production of protective antibody, the ␤-(Man)3-Fba, ␤-(Man)3-Met6 and ␤-(Man)3-Hwp1 induced protection evidenced by survival and reduced kidney fungal burden, the ␤-(Man)3-Eno1 and ␤-(Man)3-Gap1 gave moderate protection, and the ␤-(Man)3-Pgk1 slightly enhanced disease. For the ␤-(Man)3-Fba conjugate, protection was uniquely acquired through immunity against the carbohydrate and the Fba peptide. This approach based on fully synthetic chemically defined immunogens should be generally useful in vaccine development.
T
he rising incidence of life-threatening fungal diseases and associated high treatment failure rate are providing impetus for development of antifungal vaccines as a preventive strategy (1) . Whereas some vaccines are constructed to induce cell mediated immunity, others favor protective antibody responses.
The role of antibody immunity against fungal disease has been controversial (1, 2) , which is likely because of a lack of appreciation for critical parameters such as antibody specificity, isotypes and titers and the relationship between humoral and cell mediated immunity (3) . The less understood phenomenon of immunoglobulins that may cause tissue damage provides additional complexity. IgE may represent one example, but although a relationship between allergic hypersensitivity and recurrent vaginal candidiasis has been speculated (4), the role in systemic or disseminated mycotic diseases requires more investigation. We showed that certain IgM and IgG 1 antibodies with anti-mannan specificity may not be protective against disseminated candidiasis (5, 6) , but whether other antibody classes and specificity enhance disease progression is unknown. Nonetheless, in recent years, attention to these various details has resulted in solid evidence for antibody defense against candidiasis and cryptococcosis, and perhaps other mycoses (1) . Active immunization promoting positive humoral immune responses has mostly involved fungal surface antigens, including carbohydrates and proteins (5, (7) (8) (9) (10) (11) . Here, we have focused on candidiasis, which is the fourth leading cause of nosocomial blood stream infections; it causes mucosal disease in AIDS patients and Ͼ70% of females will experience one or more bouts of vulvovaginal candidiasis during their life (12) .
We previously demonstrated that complement-fixing antibodies that recognize ␤-1,2-linked mannotriose [␤-(Man) 3 ] and ␤-1,2-linked mannobiose of the cell wall phosphomannan complex of Candida albicans, and a few other Candida species, protect against hematogenously disseminated candidiasis and vaginal infection in mouse models (5, (13) (14) (15) (16) . The ␤-(Man) 3 was chosen as the vaccine carbohydrate epitope, but unconjugated oligosaccharides are poorly immunogenic (5) . Fungal cell wall peptides were sought that would serve as carriers and to provide an additional protective epitope. The latter attribute would induce protection against fungal strains not producing the carbohydrate epitope, especially because that moiety is not essential for C. albicans growth (17) and only Ϸ80% of isolates of C. glabrata, another important agent of candidiasis, produce ␤-linked mannosides (18) . To satisfy these features, a highly efficient conjugation chemistry was developed. This allowed the facile conjugation of unprotected ␤-(Man) 3 with six candidate peptide carriers derived from the cell wall of C.
albicans. An antigen-pulsed dendritic cell (DC)-based vaccine strategy elicited specific antibody against both epitopes and thereby induced protective immunity in mice against candidiasis.
Results
Oligosaccharide-Peptide Glycoconjugates. Our conjugation strategy allowed the efficient coupling of the two completely deprotected synthetic components-antigenic ␤-(Man) 3 and specific T Hpeptide epitopes-as the last step of the synthesis (19) . This strategy readily permits the screening of a range of peptide carriers and facilitates the identification of the most suitable peptides. The heterobifunctional coupling reagent (1) (Fig. 1 ) is based on a water-soluble triethylene glycol core functionalized at one end with an N-hydroxysuccinimide ester and a sulfhydryl-reactive acrylate moiety at the other (19) . This linker permits efficient coupling of biomolecules under aqueous conditions while affording, as far as possible, an immunologically silent tether.
Assembly of a panel of antifungal vaccine candidates used a convenient readily scaled synthesis of the ␤-1,2-mannopyranosyl trisaccharide as an allyl glycoside (20) . The allyl glycoside was further reacted with cysteinamine to incorporate an aminofunctionalized tether (I) that allows for the conjugation with heterobifunctional linker 1. Subsequent conversion with 1 in an aqueous buffer system furnished the stable building block 2, which was obtained after purification by preparative HPLC. The tether bound acrylate moiety incorporated in this way reacted smoothly under mild, aqueous conditions with a set of thiopropionic acid N-terminated peptide epitopes (II) prepared by solid-phase synthesis to form a nonimmunogenic thioether linkage (21) . The pure, synthetic target glycoconjugates were obtained in yields between 64 and 81% after preparative HPLC (Fig. 1). [For details of the chemical synthesis see supporting information (SI).]
C. albicans carrier proteins were selected from previously identified cell wall proteins that are expressed during pathogenesis of human disseminated candidiasis (22, 23) . The selected six candidate carriers were fructose-bisphosphate aldolase (Fba); methyltetrahydropteroyltriglutamate (Met6); hyphal wall protein-1 (Hwp1); enolase (Enol); glyceraldehyde-3-phosphate dehydrogenase (Gap1); and phosphoglycerate kinase (Pgk1). By application of an epitope-finding algorithm (GenScript, Antigen Design Tool, OptimumAntigen), putative epitopes were selected comprised of 14 aa each located near the N terminus ( Fig. 1) as we presumed that this location might be accessible to the host immune system. Each peptide shows 100% homology only with C. albicans and none has identity with mammalian proteins (data not shown). Peptides Fba, Met6 and Pgk1 contain obligatory P1 anchor residues and are predicted to bind HLA-DR (http:// bioinformatics.uams.edu/mirror/propred/index.html), and multiple MHC class I binding sites are predicted for all six peptides (www.imtech.res.in/raghava/propred1) (24, 25) .
Six Glycopeptide Conjugates Were Immunogenic in BALB/c Mice. The antigen-pulsed dendritic cell (DC)-based vaccine strategy was used in all immunizations for development of antibodies in mice. To determine the immunogenic efficacy of each, immune sera were tested for antibodies specific for the whole conjugates, synthetic ␤-(Man) 3 , synthetic peptide carriers and fungal cell surface phosphomannoprotein (PMP) extract from C. albicans cell walls (Fig. 2) . Surprisingly, all six conjugates were immunogenic as shown by high titers of specific antibody to each of the test antigens (Fig. 2) . Also, each antiserum, but not negative control sera, reacted directly with yeast and hyphal forms of the fungus as evidenced by indirect immunofluorescence microscopy (data not shown). The antibody response to the glycoconjugates was several fold greater over that of sera from control groups consisting of mice injected with buffer (Dulbecco's PBS), DCs alone, adjuvant alone (CFA) or DCsϩCFA without antigen. Our previous work showed the protective potential of antibodies specific for ␤-(Man) 3 , and the presence of these antibodies in the sera from vaccinated animals was confirmed by dose-response ELISA inhibition as described in ref. 16 (data not shown).
Vaccination with Glycopeptide Conjugates Showed Protection Against
Experimental Disseminated Candidiaisis in Mice. The immunological properties of the conjugates prompted us to assess their potential in a vaccination strategy for disseminated candidiasis. Fourteen days after the second booster, the mice were challenged intravenously (i.v.) with a lethal dose (5 ϫ 10 5 ) of viable yeast forms of C. albicans that eventually killed all control mice. Conjugateimmunized animals, except for those that received the ␤-(Man) 3 -Pgk1, survived longer than each of four control groups consisting of DPBS alone, DCs alone, CFA alone or DCsϩCFA alone.
The immunized groups that received the ␤-(Man) 3 -Hwp1, ␤-(Man) 3 -Fba, or ␤-(Man) 3 -Met6 conjugates showed 80Ϫ100% survival throughout the 120 day postchallenge observation period ( Fig. 3 ). Mice that received either ␤-(Man) 3 -Enol or ␤-(Man) 3 -Gap1 showed 40Ϫ80% survival. However, control groups given DPBS, DCs alone, CFA alone or DCsϩCFA without antigen, or mice given the ␤-(Man) 3 -Pgk1 conjugate, had median survival times of 5, 6, 14, 16, and 11 days, respectively. Importantly, the survivors had greatly reduced or even nondetectable viable fungal units (colony forming units, CFU) in kidneys, a target organ in disseminated candidiasis, compared with animals that succumbed (P Ͻ 0.0001). The exception to the above trend exemplified by ␤-(Man) 3 -Pgk1 is in itself interesting. These animals died by day 13 after challenge compared with day 40 for the DCϩCFA control. In a repeat experiment the numbers were 16 and 26 days for ␤-(Man) 3 -Pgk1 immunized mice and controls, respectively (Fig. 3) .
To confirm that induced antibodies were protective, sera from mice immunized against the ␤-(Man) 3 -Fba conjugate were transferred to naïve mice as before (5, 26) and challenged with live C. albicans. These mice had significantly prolonged survival times and reduced kidney fungal colony counts compared with those that received serum from nonimmunized controls or antiserum preabsorbed with fungal cells before challenge (Fig. 4) .
Vaccination with the Fba Peptide Induced Antibody Production and Protection Against Disease. The previous results led us to consider whether protection was restricted to responses against the mannotriose, or whether responses to the carrier peptide also contributed. The Fba peptide and the synthetic ␤-(Man) 3 were used independently to pulse DCs for subsequent immunizations. The peptide induced relatively strong specific antibody responses (Fig.  5 ) that were not cross-reactive with ␤-(Man) 3 (data not shown), whereas mice immunized against the mannotriose without carrier produced, as expected, only minimal antibody titers (Fig. 5) . Both test groups survived longer than DPBS controls following an i.v. challenge with live fungal cells, but all mice that received peptide survived. Based on our earlier findings that antibodies specific for the ␤-(Man) 3 can be protective against candidiasis (5, 14, 27) , the relatively high trisaccharide-specific titers in protected mice following immunization with three of the conjugates (Fig. 3) , ability to passively transfer protection to naïve mice, and slight protection in mice that developed low antibody titers to the mannotriose alone, led us to conclude that the ␤-(Man) 3 -Fba conjugate induced protective antibody specific for the ␤-(Man) 3 part of the vaccine conjugate. This conclusion was further strengthened by an extended observation in which neither the Gap1 nor the Eno1 peptide alone induced protection against disseminated candidiasis (data not shown), yet the ␤-(Man) 3 -peptide conjugate of each induced high titers of anti-␤-(Man) 3 antibodies that correlated with an intermediate to high
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-M e t6 . Serum samples were collected from vaccinated mice and controls 14 days after immunization, diluted 1:100 and tested by ELISA. Sera from groups of mice injected with DPBS, DCs, CFA, DCsϩCFA were used as negative controls. Each data point represents the immunoreactivity per mouse; the mean of optical density (492 nm) for each group is indicated by the horizontal bars. Antibody levels were tested in duplicate in three independent experiments and the results were comparable.
level of protection against disease (Fig. 3) . These various results indicate that both epitopes that comprise the synthetic vaccine induce independent and favorable responses against candidiasis.
Discussion
Six chemically defined glycopeptide vaccine conjugates have been prepared by a convenient and efficient conjugation strategy that avoids aromatic or other cyclic structural elements (28) that can themselves elicit a strong humoral immune response, which may suppress the desired antibody response against the target epitopes (29-31). Each synthetic conjugate comprised a ␤-linked mannotriose (glycan) epitope corresponding to the Candida albicans cell wall ␤-mannan, a unique, nonimmunogenic linker, and one of six selected peptide carriers derived from cell wall proteins of the fungus that are known to be expressed during pathogenesis of human candidiasis. When tested for their ability to protect experimental animals against hematogenously disseminated candidiasis following a dendritic cell (DC) immunization these putative vaccine candidates produced antibody against the glycan epitope and the carrier peptide. Presumably responses against both epitopes can be anticipated because DCs present peptide epitopes via the MHC class II pathway. In our case, expression of mannose receptor (MR) on the DC surface was also likely advantaged because of its recognition of N-linked mannosyl residues (32), of which the ␤-linked mannotriose is a part (33) . In preliminary work, we determined that the synthetic ␤-linked mannotriose coupled to protein carriers, such as BSA, were poorly immunogenic in mice even when given with complete Freund adjuvant. The antigenpulsed DC immunization approach, however, proved to be a powerful way of overcoming the relatively weak immune response of the mouse to the defined small carbohydrate and peptide antigens of C. albicans. The work reported here is intriguing from a number of standpoints. First, our results are in sharp contrast to observations that suggest glycoconjugate vaccines be constructed from oligosaccharides consisting of multiple repeating units ranging in size from 8 up to 200 saccharide residues (13) (14) (15) (16) . Here, we show the feasibility of generating a synthetic glycopeptide-based vaccine where peptide and saccharide components are small and chemically defined by standard techniques such as NMR and mass spectrometry. In this case, we demonstrated utility in development of a vaccine against a fungal disease, but the process should be applicable to glycopeptide vaccine development in general. Second, the immunization approach that induces robust antibody responses to otherwise poorly immunogenic vaccines should be generally applicable to vaccine development in mouse models of human disease. Third, the work establishes the usefulness of epitope-finding algorithms for development of synthetic vaccines. That is, identification of an appropriate peptide carrier epitope lends itself to rapid synthesis in the laboratory and potentially obviates the need for working with large recombinant antigenic/carrier proteins. In fact, use of this approach led both to the identification of potentially useful vaccine candidates against candidiasis and the surprising finding of one conjugate, ␤-(Man) 3 -Pgk1 that enhanced disease susceptibility. This latter intriguing observation merits more investigation as it may yield insights, in addition to those discovered earlier in our lab (5, 14) into mechanisms by which antibody or other immune responses against C. albicans may not be of benefit to the host. Although we do not know a cause for the enhanced disease, the mechanism does not appear to be related to IgE induction because this Ig isotype was not enhanced in sera of immunized mice (data not shown). Regardless, the approaches outlined here allow for rapid screening of multiple peptide carriers to determine which will lead to optimal host immune responses. Finally, while synthetic glycopeptide vaccines reported by others induce potentially protective antibody responses against only the carbohydrate epitope of the vaccine conjugate (34, 35) , at least one conjugate reported here uniquely induces protective responses against both the carbohydrate and peptide carrier components. Developers of glycan-based vaccines commonly employ bacterial toxoids, such as that of tetanus or diphtheria, as the protein carrier molecule (34, 36, 37) . The immunological universality of these carriers and acceptance for human use are distinct advantages. An advantage of our approach is that the peptide carrier is derived from the infectious agent of interest, providing the possibility of a dual protective immune response against both the glycan epitope and the peptide carrier.
In conclusion, our work shows the potential for chemical synthesis of relatively small molecular weight vaccines that induce protection against more than one unrelated epitope expressed by the infectious disease agent of interest.
Materials and Methods
Organism and Culture Conditions. C. albicans 3153A (ATCC 28367) was grown as stationary-phase yeast cells in glucose-yeast extract-peptone broth at 37°C, washed and suspended in cold Dulbecco's PBS (DPBS; Sigma), and used to infect mice as described (5, 15) .
Mice. BALB/c female mice (National Cancer Institute Animal Production Program or Harlan) 5 to 7 weeks old were used throughout. Mice were maintained and handled in accordance with a protocol approved by the Institutional Animal Care and Use committee (IACUC) regulations at Children's Hospital Research Institute in New Orleans.
Synthetic Glycopeptide Vaccines. Six cell wall proteins were selected as possible carriers on the basis of their known expression during pathogenesis of human candidiasis a cell wall location (22, 23) and included: hyphal wall protein-1 (Hwp1); enolase (Enol); phosphoglycerate kinase (Pgk1); glyceraldehyde-3-phosphate dehydrogenase (Gap1); fructose-bisphosphate aldolase (Fba); and methyltetrahydropteroyltriglutamate (Met6). By application of an epitopefinding algorithm (www.genscript.com/cgibin/tools/antigenicprediction.pl), we selected the following 14-mer peptides for synthesis, all of which are located near the N terminus of each protein group: Hwp1, QGETEEALIQKRSY; Eno1, DSRGNPTVEVDFTT; Pgk1, VPLDGKTITNNQRI; Gap1, NRSPSTGEQKSSGI; Fba, YGK-DVKDLFDYAQE; and, Met6, PRIGGQRELKKITE. Synthetic peptides were produced commercially (GenScript) or synthesized in our laboratory by use of an automated peptide synthesizer. Glycopeptides were synthesized by a conjugation procedure of which more details are presented in the SI and in reference (19) . In brief, resin bound peptides were assembled with an automated synthesizer and after completion of the corresponding peptide sequence, S-trityl protected mercaptopropionic acid was coupled to install a sulfhydryl moiety to serve as attachment point for conjugation of the ␤-mannan trisaccharide epitope. The latter was synthesized as an allyl glycoside and subsequently reacted to provide a triethylene glycol tether terminated by an acrylate ester. The ␤-mannotriose-peptide (glycopeptide) conjugates were formed in high yield by reacting the deprotected oligosaccharide derivative with the thiol terminated peptide. All glycopeptides were purified by RP-HPLC, and their purity and identity confirmed by analytical HPLC, mass spectrometry Evidence that responses against a peptide carrier contributes to protection. Mice immunized with ␤-1,2-mannotriose-pulsed DCs or synthetic peptide Fba-pulsed DCs for the priming and first booster immunization followed by each respective epitope emulsified in CFA for the second booster produced antibodies and showed protection. The sera from the immunized mice were tested for the presence of antibodies specific for phosphomannoprotein (PMP) extract from C. albicans cell walls and synthetic peptide by ELISA, and for their ability to induce protection against disseminated candidiasis. (A and B) ELISA titers, done on plates coated with either synthetic peptide (A) or PMP extract of C. albicans strain 3153A (B) showed relatively strong specific antibody responses (diamonds) against both the peptide and PMP extract compared with DPBS control mice (triangles), whereas mice immunized against the ␤-linked mannotriose alone produced only minimal anti-PMP extract antibody titers (squares). (C) Mice immunized against the mannotriose alone survived slightly longer than DPBS control mice, which was expected by the low antibody response to mannotriose alone, whereas animals that were immunized with Fba peptide alone gave 100% survival throughout the observation period.
and for selected examples by NMR. For ease of reference the conjugates were designated as ␤-(Man)3-Hwp1, ␤-(Man)3-Enol, ␤-(Man)3-Gap1, ␤-(Man)3-Pgk1, ␤-(Man)3-Fba, ␤-(Man)3-Met6. Details of the chemical synthesis and analytical data of the compounds are provided in the SI section.
Isolation and Culture of Dendritic Cells (DC) from Mouse Bone Marrow. DCs were generated from bone marrow by a previously described method (38, 39) , with some modifications. Briefly, bone marrow flushed with RPMI-1640 from the long bones of euthanized mice was gently pipetted and filtered through a 70-mm cell strainer to dissociate cell clusters. Red blood cells were lysed (ACK lysing buffer, 0.15 M NH4Cl, 1.0 mM KHCO3, 0.1 mM EDTA) and remaining bone marrow cells were suspended in complete medium [CM, RPMI-1640 supplemented with 10% FBS (FBS), 2 mM L-glutamine, 1% of nonessential amino acids and 100 units/ml penicillin and 100 mg/ml streptomycin], adjusted to 2 ϫ 10 5 cells per ml, plated in 6-well plates at 5 ml per well and cultured for up to 9 days in the presence of 40 ng/ml of rmGM-CSF and rmIL-4 (R&D Systems) at 37°C, 5% CO2. On days 4 and 7 of culture, the same amount of fresh GM-CSF and IL-4 was added to the wells. To isolate the DC population, the cells were suspended in 2-4 ml of warm CM, overlaid onto the same volume of 14.5% (wt/vol) Nycodenz (Sigma) in CM and centrifuged at 1,200 ϫ g for 20 min at 22°C. After centrifugation, cells in the interface were collected, washed with CM three times and subjected to phenotypic and functional analyses. Flow cytometric analysis and the use of MAbs specific for CD11c, CD11b, CD19 and CD3e (eBioscience) showed that Ͼ80% of the cells were DCs.
Immunogens and Immunizations. DCs were pulsed in vitro with vaccines as described (40, 41) and with our modifications. Briefly, DCs in culture were pulsed with the antigen of choice (1 M) on day 6. On day 7, PGE2 (10 Ϫ7 -10 Ϫ9 M) was added along with LPS (2 g/ml, Sigma) for 24h. On day 9, antigen-pulsed DCs were washed extensively and 5 ϫ 10 5 in 200 l DPBS were given i.p. (ip). The mice were boosted at day 14 with fresh antigen-pulsed DCs and boosted a second time at day 28 with antigen (10 g) emulsified in complete Freund adjuvant (CFA).
Serological Assays. Sera were ELISA analyzed for antibody titers. Control groups consisted of mice given DCs alone at the time of priming and first booster followed by DPBS at the time of the second booster, DPBS for the priming and first booster and CFA alone at the time of the second booster, DPBS alone for all three injections, or DCs alone for priming and first booster followed by CFA alone at the time of the second booster. Briefly, C. albicans PMP extract (13) , which is composed mainly of mannan, but also 12Ϫ20% protein, was dissolved at 10 g/ml in carbonate buffer (pH 9.6). The glycopeptide conjugates, ␤-(Man)3-BSA or synthetic peptides were dissolved at 10 g/ml in PBS (pH 7.4). Each was used to coat 96-well ELISA plates for testing duplicate serial 2-fold dilutions of samples of each immune serum and control sera. Color development for each well was achieved by secondary antibody (goat anti-mouse polyvalent Ig-HRP, Sigma) and substrate (O-phenylenediamine and H 2O2) and OD determined at 492 nm.
Fungal Challenge and Assessment of Protection. Two weeks after the second boost, immune and control mice were infected i.v. with a lethal dose of live C. albicans yeast cells (5 ϫ 10 5 in 0.1 ml of DPBS) as described in ref. 41 . Passively immunized mice (below) also received the same challenge dose. Protection was evaluated by monitoring animal survival for up to 120 days and by quantifying the number of CFU (mean Ϯ SE) per kidney pairs (5, 27, 42) .
Protection Against Candida Infections by Passive Transfer. Pooled serum from ␤-(Man)3-Fba immunized mice was ELISA titered as described above. Passive immunization was performed by single i.p. administration of 0.5 ml of the pooled antiserum, or antiserum preadsorbed with yeast as a control (5, 15, 27) , 4 h before i.v. challenge with C. albicans. Infected mice were killed when they became moribund and their kidneys were assessed for CFUs.
Statistical Analysis. Median survival times (MST) were statistically evaluated by Kaplan-Meier (GraphPad Prism, version 4). In all analyses, there were five mice per group (n ϭ 5) and a two-tailed t test was used.
